• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 73Patient flow through trials–perphenazine versus risperidone

Intervention #1Intervention #2Intervention #3Intervention #4Intervention #5Intervention #6
Ascher–Svanum et al. 2008131ClassificationFGASGA
MedicationPerphenazineRisperidone
DosageNRNR
No screened:NR
No randomized:48221
No completed:48217
No analyzed (E):48217
No analyzed (S):NRNR
Lieberman et al. 200523ClassificationFGASGASGASGASGA
MedicationPerphenazineOlanzapineQuetiapineRisperidoneZiprasidone
Dosage8–32mg/d7.5–30mg/d200–800mg/d1.5–6.0mg/d40–160mg/d
No screened:1894
No randomized:261336337341185
No completed:65120608838
No analyzed (E):257330329333183
No analyzed (S):261336337341185

d = day; E = efficacy; FGA = first-generation antipsychotic; mg = milligram; No = number; NR = not reported; S = safety; SGA = second-generation antipsychotic

From: Appendix I, Patient Flow Through Trials

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 63.
Abou-Setta AM, Mousavi SS, Spooner C, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.